TSX lower as gold rally takes a breather
Investing.com - H.C. Wainwright has reiterated its Buy rating and $5.00 price target on Prelude Therapeutics (NASDAQ:PRLD), citing upcoming catalysts expected by the end of 2025. Currently trading at $1.01, the stock appears undervalued according to InvestingPro analysis, with significant upside potential to the analyst’s target.
The firm highlighted two key upcoming events: the presentation of final results from the Phase 1 trial evaluating PRT3789 in biomarker-selected SMARCA4-mutated cancers, and initial interim data from the Phase 1 trial of PRT7732, an orally bioavailable SMARCA2 degrader. While the company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 3.68, InvestingPro data indicates rapid cash burn remains a concern.
Prelude has selected the 500mg QW dose as the recommended Phase 2 dose for PRT3789, with updated results showing dose-dependent increases in exposure and deeper, more prolonged SMARCA2 degradation in patient PBMCs across 69 patients with a median of three prior treatments.
Efficacy data revealed that among 13 non-small cell lung cancer (NSCLC) or upper GI cancer patients treated at doses above 283mg, confirmed partial responses were observed in three patients - one with gastric cancer and two with lung cancer - representing a 23.1% confirmed objective response rate.
The research note specifically addressed patients with Class 1 (loss-of-function) mutations, which represented 56.5% of the study population receiving PRT3789 treatment. Get access to comprehensive analysis and 13 additional key insights about PRLD through the detailed InvestingPro Research Report, helping you make more informed investment decisions.
In other recent news, Prelude Therapeutics Incorporated has successfully regained compliance with the Nasdaq Stock Market’s minimum bid price requirement. This development was confirmed after the company received a letter from Nasdaq on September 18, 2025, indicating that Prelude Therapeutics now meets the listing standard. The requirement stipulates a minimum bid price of $1.00 per share, as outlined under Nasdaq Listing Rule 5550(a)(2). Prelude Therapeutics had previously been notified on March 27, 2025, of its non-compliance with this rule, following a period during which its common stock failed to maintain the required closing bid price. This compliance is a key regulatory milestone for the company, ensuring its continued listing on the Nasdaq exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.